Dr. Olatoyosi M. Odenike
Claim this profileUniversity of Chicago Comprehensive Cancer Center
Area of expertise
Acute Myeloid Leukemia
Olatoyosi M. Odenike has run 7 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
Acute Myelogenous Leukemia
Olatoyosi M. Odenike has run 6 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
Affiliated Hospitals
University Of Chicago Comprehensive Cancer Center
The University Of Chicago
Clinical Trials Olatoyosi M. Odenike is currently running
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting
1 award
Phase 2
17 criteria
SNDX-5613 + Chemotherapy
for Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-5613 blocks signals passed from one molecule to another inside cancer cells that are needed for cancer cell survival. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding SNDX-5613 to the standard chemotherapy treatment may be able to shrink or stabilize the cancer for longer than the standard chemotherapy treatment alone.
Recruiting
1 award
Phase 1
More about Olatoyosi M. Odenike
Clinical Trial Related
21 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Olatoyosi M. Odenike has experience with
- Venetoclax
- Azacitidine
- Cytarabine
- Daunorubicin Hydrochloride
- Decitabine
- Selumetinib
Breakdown of trials Olatoyosi M. Odenike has run
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Myeloproliferative Disorder
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Olatoyosi M. Odenike specialize in?
Olatoyosi M. Odenike focuses on Acute Myeloid Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved TP53 positive patients, or patients who are MLL positive.
Is Olatoyosi M. Odenike currently recruiting for clinical trials?
Yes, Olatoyosi M. Odenike is currently recruiting for 5 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Olatoyosi M. Odenike has studied deeply?
Yes, Olatoyosi M. Odenike has studied treatments such as Venetoclax, Azacitidine, Cytarabine.
What is the best way to schedule an appointment with Olatoyosi M. Odenike?
Apply for one of the trials that Olatoyosi M. Odenike is conducting.
What is the office address of Olatoyosi M. Odenike?
The office of Olatoyosi M. Odenike is located at: University of Chicago Comprehensive Cancer Center, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.